NOVABAY PHARMACEUTICALS INC (NBY) Fundamental Analysis & Valuation

NYSEARCA:NBY • US66987P4090

Current stock price

1.95 USD
+0.36 (+22.64%)
At close:
1.98 USD
+0.03 (+1.54%)
After Hours:

This NBY fundamental analysis includes valuation metrics, fair value assessment, financial health analysis, profitability trends, growth metrics and dividend sustainability analysis.

1

1. NBY Profitability Analysis

1.1 Basic Checks

  • In the past year NBY has reported negative net income.
  • In the past year NBY has reported a negative cash flow from operations.
  • In the past 5 years NBY always reported negative net income.
  • NBY had negative operating cash flow in 4 of the past 5 years.
NBY Yearly Net Income VS EBIT VS OCF VS FCFNBY Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 -5M -10M -15M

1.2 Ratios

  • NBY has a worse Return On Assets (-95.27%) than 77.08% of its industry peers.
Industry RankSector Rank
ROA -95.27%
ROE N/A
ROIC N/A
ROA(3y)-178.5%
ROA(5y)-127.06%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
NBY Yearly ROA, ROE, ROICNBY Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 2K 4K 6K

1.3 Margins

  • Looking at the Gross Margin, with a value of 66.26%, NBY is in the better half of the industry, outperforming 73.44% of the companies in the same industry.
  • In the last couple of years the Gross Margin of NBY has declined.
  • The Profit Margin and Operating Margin are not available for NBY so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 66.26%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-2.12%
GM growth 5Y-2.09%
NBY Yearly Profit, Operating, Gross MarginsNBY Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 50 -50 -100 -150

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

3

2. NBY Health Analysis

2.1 Basic Checks

  • NBY does not have a ROIC to compare to the WACC, probably because it is not profitable.
  • NBY has more shares outstanding than it did 1 year ago.
  • Compared to 5 years ago, NBY has more shares outstanding
  • The debt/assets ratio for NBY has been reduced compared to a year ago.
NBY Yearly Shares OutstandingNBY Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 5M 10M 15M 20M 25M
NBY Yearly Total Debt VS Total AssetsNBY Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 5M 10M 15M 20M

2.2 Solvency

  • NBY has an Altman-Z score of -31.38. This is a bad value and indicates that NBY is not financially healthy and even has some risk of bankruptcy.
  • With a Altman-Z score value of -31.38, NBY is not doing good in the industry: 87.50% of the companies in the same industry are doing better.
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Altman-Z -31.38
ROIC/WACCN/A
WACC9.38%
NBY Yearly LT Debt VS Equity VS FCFNBY Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 10M -10M -20M

2.3 Liquidity

  • A Current Ratio of 7.60 indicates that NBY has no problem at all paying its short term obligations.
  • NBY has a Current ratio of 7.60. This is in the better half of the industry: NBY outperforms 77.08% of its industry peers.
  • A Quick Ratio of 7.60 indicates that NBY has no problem at all paying its short term obligations.
  • NBY has a Quick ratio of 7.60. This is in the better half of the industry: NBY outperforms 77.08% of its industry peers.
Industry RankSector Rank
Current Ratio 7.6
Quick Ratio 7.6
NBY Yearly Current Assets VS Current LiabilitesNBY Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 5M 10M

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

6

3. NBY Growth Analysis

3.1 Past

  • NBY shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 98.17%, which is quite impressive.
  • NBY shows a very negative growth in Revenue. In the last year, the Revenue has decreased by -33.58%.
  • NBY shows quite a strong growth in Revenue. Measured over the last years, the Revenue has been growing by 8.19% yearly.
EPS 1Y (TTM)98.17%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%24.84%
Revenue 1Y (TTM)-33.58%
Revenue growth 3Y5.12%
Revenue growth 5Y8.19%
Sales Q2Q%-100%

3.2 Future

  • The Earnings Per Share is expected to grow by 31.55% on average over the next years. This is a very strong growth
  • The Revenue is expected to grow by 21.46% on average over the next years. This is a very strong growth
EPS Next Y39.01%
EPS Next 2Y31.55%
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next Year11.73%
Revenue Next 2Y21.46%
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

  • The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.
NBY Yearly Revenue VS EstimatesNBY Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 5M 10M 15M
NBY Yearly EPS VS EstimatesNBY Yearly EPS VS EstimatesYearly EPS VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 -10K -20K -30K -40K

More info and screens

Find the best growth stocksShow best growing peers

1

4. NBY Valuation Analysis

4.1 Price/Earnings Ratio

  • The Price/Earnings Ratio is negative for NBY. In the last year negative earnings were reported.
  • Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for NBY. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
NBY Price Earnings VS Forward Price EarningsNBY Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
NBY Per share dataNBY EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 -2 -4 -6 -8 -10

4.3 Compensation for Growth

  • A more expensive valuation may be justified as NBY's earnings are expected to grow with 31.55% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y31.55%
EPS Next 3YN/A

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

4

5. NBY Dividend Analysis

5.1 Amount

  • With a Yearly Dividend Yield of 41.03%, NBY is a good candidate for dividend investing.
  • The stock price of NBY dropped by -93.36% in the last 3 months. With lower prices the dividend yield is higher, but it may be a sign investors do not trust the long term dividend.
  • Compared to an average industry Dividend Yield of 0.64, NBY pays a better dividend. On top of this NBY pays more dividend than 100.00% of the companies listed in the same industry.
  • Compared to an average S&P500 Dividend Yield of 1.89, NBY pays a better dividend.
Industry RankSector Rank
Dividend Yield 41.03%

5.2 History

  • NBY does not have a reliable dividend history as it only pays dividend since a couple or years.
Dividend Growth(5Y)N/A
Div Incr Years0
Div Non Decr Years0
NBY Yearly Dividends per shareNBY Yearly Dividends per shareYearly Dividends per share 2025 0 0 0 0 0

5.3 Sustainability

DP0%
EPS Next 2Y31.55%
EPS Next 3YN/A
NBY Yearly Income VS Free CF VS DividendNBY Yearly Income VS Free CF VS DividendYearly Income VS Free CF VS Dividend 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 -5M -10M -15M

More info and screens

Find the best dividend stocksShow peers with best dividend

NBY Fundamentals: All Metrics, Ratios and Statistics

NOVABAY PHARMACEUTICALS INC

NYSEARCA:NBY (4/2/2026, 8:04:00 PM)

After market: 1.98 +0.03 (+1.54%)

1.95

+0.36 (+22.64%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)03-31
Earnings (Next)05-13
Inst Owners5.45%
Inst Owner Change1891.11%
Ins Owners4.89%
Ins Owner Change0%
Market Cap50.93M
Revenue(TTM)9.78M
Net Income(TTM)-8.61M
Analysts80
Price TargetN/A
Short Float %N/A
Short Ratio0.23
Dividend
Industry RankSector Rank
Dividend Yield 41.03%
Yearly Dividend0.37
Dividend Growth(5Y)N/A
DP0%
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)0
Avg Revenue beat(2)-91.4%
Min Revenue beat(2)-100%
Max Revenue beat(2)-82.81%
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)0%
EPS NQ rev (3m)0%
EPS NY rev (1m)0%
EPS NY rev (3m)0%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)0%
Revenue NY rev (1m)0%
Revenue NY rev (3m)0%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 5.21
P/FCF N/A
P/OCF N/A
P/B N/A
P/tB N/A
EV/EBITDA N/A
EPS(TTM)-12.67
EYN/A
EPS(NY)-0.38
Fwd EYN/A
FCF(TTM)-0.16
FCFYN/A
OCF(TTM)-0.16
OCFYN/A
SpS0.37
BVpS-0.87
TBVpS-0.87
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -95.27%
ROE N/A
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 66.26%
FCFM N/A
ROA(3y)-178.5%
ROA(5y)-127.06%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-2.12%
GM growth 5Y-2.09%
F-Score5
Asset Turnover1.08
Health
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 15%
Cap/Sales 0.06%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 7.6
Quick Ratio 7.6
Altman-Z -31.38
F-Score5
WACC9.38%
ROIC/WACCN/A
Cap/Depr(3y)15.76%
Cap/Depr(5y)29.79%
Cap/Sales(3y)0.32%
Cap/Sales(5y)0.37%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)98.17%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%24.84%
EPS Next Y39.01%
EPS Next 2Y31.55%
EPS Next 3YN/A
EPS Next 5YN/A
Revenue 1Y (TTM)-33.58%
Revenue growth 3Y5.12%
Revenue growth 5Y8.19%
Sales Q2Q%-100%
Revenue Next Year11.73%
Revenue Next 2Y21.46%
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y0.58%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year51.27%
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y-11.31%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-11.71%
OCF growth 3YN/A
OCF growth 5YN/A

NOVABAY PHARMACEUTICALS INC / NBY Fundamental Analysis FAQ

Can you provide the ChartMill fundamental rating for NOVABAY PHARMACEUTICALS INC?

ChartMill assigns a fundamental rating of 3 / 10 to NBY.


What is the valuation status of NOVABAY PHARMACEUTICALS INC (NBY) stock?

ChartMill assigns a valuation rating of 1 / 10 to NOVABAY PHARMACEUTICALS INC (NBY). This can be considered as Overvalued.


How profitable is NOVABAY PHARMACEUTICALS INC (NBY) stock?

NOVABAY PHARMACEUTICALS INC (NBY) has a profitability rating of 1 / 10.


Can you provide the financial health for NBY stock?

The financial health rating of NOVABAY PHARMACEUTICALS INC (NBY) is 3 / 10.